Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947445 | 0.93 | ALDH1A1 (0.51) | ALDH1A1CYP2C19LMNATDP1HTT | |
| SCHEMBL30875689 | 0.90 | ALDH1A1 (0.50) | ALDH1A1CYP2C19LMNATDP1HTT | |
| SCHEMBL11302461 | 0.90 | ALDH1A1 (0.50) | ALDH1A1CYP2C19LMNATDP1HTT | |
| SCHEMBL2729882 | 0.87 | ALDH1A1 (0.47) | ALDH1A1CYP2C19LMNATDP1HTT | |
| SCHEMBL2729877 | 0.87 | ALDH1A1 (0.47) | ALDH1A1CYP2C19LMNATDP1HTT | |
| SCHEMBL5700815 | 0.86 | ALDH1A1 (0.48) | ALDH1A1CYP2C19LMNATDP1HTT | |
| SCHEMBL2597743 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAKMT2APOLBL3MBTL1 | |
| SCHEMBL16413095 | 0.84 | ALDH1A1 (0.66) | ALDH1A1CYP2C19LMNAKMT2A | |
| SCHEMBL3313171 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CYP2C19LMNATDP1HTT | |
| SCHEMBL7684130 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP2C19LMNATDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER3, HTR4 | ALDH1A1 1264/4885CYP2C19 284/4885LMNA 2184/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | ALDH1A1 649/4885CYP2C19 61/4885LMNA 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.